According to our latest study on "Parenteral Nutrition Market Forecast to 2030 - Global Analysis - by Nutrient Type, and End User," the parenteral nutrition market size was valued at US$ 2.26 billion in 2022 and is expected to reach US$ 3.65 billion by 2030. The market is estimated to register a CAGR of 6.1% from 2022 to 2030. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.
Parenteral nutrition is a nutritional supplementation administered intravenously that includes fluids, vitamins, minerals, trace elements, amino acids, and electrolytes. Compared to enteral (gastric or intestinal) feeding, parenteral nutrition is more complex, more costly, and linked to a higher risk of infection and longer hospital stays. Only patients who are unable to receive nutrition enterally are prescribed parenteral nutrition. The goals of parenteral nutrition therapy include restoring nutritional status, treating hypoproteinemia, fixing muscle weakness, and replacing other nutritional deficits.
Companies operating in the parenteral medical nutrition market constantly focus on new product launches, which help them improve their sales. A few of the noteworthy developments in the parenteral nutrition market are mentioned below:
- In December 2022, Baxter International Inc introduced the ExactaMix Pro Automated Compounder in the US. The announcement was made at the 2022 Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP). The product debuted at the beginning of 2023. The recently released product uses cutting-edge compounding technology to enhance patient safety, process effectiveness, and formulation accuracy.
- In March 2022, Fresenius Kabi's SMOFlipid lipid injectable emulsion received US Food and Drug Administration (FDA) approval. The emulsion is used to provide parenteral nutrition to pediatric patients, including term and preterm neonates, which makes it the first and only four-oil lipid emulsion for pediatric patients requiring parenteral nutrition.
Thus, new product development of nutrition is anticipated to create opportunities for the market growth during the forecast period.
ICU Medical Inc., Grifols SA, Pfizer Inc., Otsuka Pharmaceuticals Co Ltd, Baxter International Inc., B Braun SE, Fresenius Kabi AG, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, Vifor Pharma Management AG, and Aculife Healthcare Pvt Ltd are among the key players operating in the global parenteral nutrition market.
The report segments the global parenteral nutrition market as follows:
The parenteral nutrition market is segmented on the basis of nutrient type and end user. The parenteral nutrition market, by nutrient type, is subsegmented into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins and minerals.
The parenteral nutrition market, by nutrient type, is segmented into carbohydrates, parenteral lipid emulsion, single dose amino acid solution, trace elements, and vitamins and minerals. The parenteral nutrition market analysis estimated that the single dose amino acid solution segment held the largest share of the market in 2022; and the parenteral lipid emulsion segment is likely to register the highest CAGR in the parenteral nutrition market during the forecast period. There is a growing need for nutrition therapies such as parenteral amino acids that deliver a substantial amount of protein, but not a toxic amount of energy, to slow down protein catabolism in critically ill patients. Amino acid supplementation is given to patients in case of insufficient amino acid intake in healthy individuals and specific physiological or pathophysiological situations. The amino acid requirement is lower in parenterally-fed infants and children than in enterally-fed infants because the supply bypasses the intestine.
In terms of end users, the parenteral nutrition market is categorized into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022; however, the clinic segment is anticipated to hold a significant parenteral nutrition market share by 2030. Hospitals are considered the largest entities that have all the facilities available. Hospitals also provide various diagnostics and treatment facilities that can be reimbursed under insurance claims. Hospitals are associated with various doctors, specialists' doctors, and other professionals who provide enhanced healthcare services. All types of cardiovascular diseases can be treated in hospitals. Hospitals serve a substantial role by providing extensive medical services, including nursing services, to patients suffering from a variety of diseases. This increased the adoption of transdermal drug delivery systems for several diseases and surgeries among patients in hospitals.
The scope of the parenteral nutrition market report covers North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Asia Pacific is expected to register the highest CAGR from 2022 to 2030. The parenteral nutrition market in Asia Pacific is expected to grow owing to the growing presence of major market players across the region and the increasing prevalence of chronic diseases. Due to these factors, the region records the highest manufacturing of parenteral nutrition products. Australia, India, South Korea, and a few other countries in the region are estimated to witness various growth opportunities due to the growing development in the healthcare sector during the forecast period. In addition, governments of these countries are increasing their efforts to provide parenteral nutrition.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com